Carlos M. Galmarini
Paseo De La Castellana 40 Pl 8
Castellana, MD 28046, Spain
Castellana, MD 28046, Spain
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 50 publications
PROCC: a predictive score to identify KRAS wild type metastatic colorectal cancer patients who are likely to obtain survival benefit from panitumumab treatment.
Journal: British journal of cancer
Published: March 05, 2025
Hereditary angioedema diagnosis evaluation score (HADES): A new clinical scoring system for predicting hereditary angioedema with C1 inhibitor deficiency.
Journal: The journal of allergy and clinical immunology. Global
Published: September 05, 2024
Analysis of transcriptomic responses to SARS-CoV-2 reveals plausible defective pathways responsible for increased susceptibility to infection and complications and helps to develop fast-track repositioning of drugs against COVID-19.
Journal: Computers in biology and medicine
Published: April 20, 2022
Deep Neural Frameworks Improve the Accuracy of General Practitioners in the Classification of Pigmented Skin Lesions.
Journal: Diagnostics (Basel, Switzerland)
Published: October 20, 2020
Why we do what we do. A brief analysis of cancer therapies.
Journal: EXCLI journal
Published: October 01, 2020
Artificial intelligence: a disruptive tool for a smarter medicine.
Journal: European review for medical and pharmacological sciences
Published: July 25, 2020
Lessons from Hippocrates: Time to Change the Cancer Paradigm.
Journal: International journal of chronic diseases
Published: December 17, 2019
Aplidin (plitidepsin) is a novel anti-myeloma agent with potent anti-resorptive activity mediated by direct effects on osteoclasts.
Journal: Oncotarget
Published: November 26, 2018
ATLANTIS: a Phase III study of lurbinectedin/doxorubicin versus topotecan or cyclophosphamide/doxorubicin/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line.
Journal: Future oncology (London, England)
Published: October 27, 2018
Multicenter Phase II Study of Lurbinectedin in BRCA-Mutated and Unselected Metastatic Advanced Breast Cancer and Biomarker Assessment Substudy.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: September 22, 2018
The Antitumor Drugs Trabectedin and Lurbinectedin Induce Transcription-Dependent Replication Stress and Genome Instability.
Journal: Molecular cancer research : MCR
Published: June 01, 2018
Last Updated: 09/26/2026